Watch the Poster Presentation:
Standardizing Starting Material: IntegriCell™ Cryopreservation Data from ISCT 2025
Watch the poster presentation video to see how automation and standardization protect cell therapy manufacturing from its riskiest variable
Cell and gene therapy manufacturing frequently begins with patient-derived leukapheresis material, yet this crucial first step is one of the most unpredictable. Conventional workflows rely on fresh leukapheresis, exposing programs to scheduling bottlenecks, patient risk, and inconsistent outcomes. At ISCT 2025, Cryoport Systems’ IntegriCell™ team presented data demonstrating how a functionally closed, automated cryopreservation process delivers consistent, high-quality starting material without compromising manufacturability.
Our findings confirm that standardized, automated cryopreservation preserves viability, recovery, and function, unlocking a more reliable future for advanced therapies.
Watch the poster presentation to see how IntegriCell™ is Preserving the Future of Medicine by redefining the starting point of cell therapy manufacturing, turning variability into control. You’ll learn:
- Why fresh leukapheresis introduces significant risks for both patients and manufacturers
- How IntegriCell™ employs a functionally closed, automated process for cryopreservation to reduce operator variability and enable scalability
- Post-thaw data demonstrating no negative impact on CAR-T manufacturing, including transduction efficiency and cytotoxic function
- How cryopreservation enables flexibility in scheduling, de-risks supply chains, and ensures every patient collection is preserved for treatment